BUSINESS

• Oral Flu Drug Prescriptions 10 Times More than Pre-COVID: August Survey
  September 15, 2023

• FDA Accepts for Review Takeda’s Entyvio SC Form for Crohn’s
  September 15, 2023

• Gilead’s Multi-Drug Resistant HIV Med Now Available in Japan
  September 14, 2023

• Xtandi Accepted for EMA Review for Earlier Type of Prostate Cancer
  September 14, 2023

• Pfizer Japan Files 20-Valent Pneumococcal Jab for Older Adults, High-Risk People
  September 14, 2023

• Daiichi Sankyo Aims to Develop ADC DS-7300 beyond Current 4 Cancers: Exec
  September 13, 2023

• GARDP, Indian Firm Ink Deal to Expand Access to Shionogi Antibiotic
  September 13, 2023

• Eisai Sets Up Digital Biz Unit to Build Dementia Ecosystem
  September 13, 2023

• Takeda Shoots for 80% Cut in Paper Materials, Switch to All-EV/HV Fleet by FY2025
  September 12, 2023

• Daiichi Sankyo’s HER3 ADC Posts Positive PII Data in 3rd Line NSCLC, US Filing Eyed by March
  September 12, 2023

• EA Pharma, China’s TransThera Hook Up on GI Drug Research
  September 12, 2023

• GSK Files Myelofibrosis Drug Momelotinib in Japan
  September 12, 2023

• China’s Haihe Makes Japan Debut with NDA Filing of Lung Cancer Drug
  September 12, 2023

• Sumitomo to Ramp Up Regenerative, Cell Therapy Biz to Counter Latuda Patent Cliff
  September 11, 2023

• Otsuka, Shape Link Up on AAV Gene Therapies for Eye Diseases
  September 11, 2023

• TA-MUC1-Directed ADC Enters Clinic for Solid Tumors: Daiichi Sankyo
  September 11, 2023

• Japan Ethical Drug Sales Up 7.9% in July: Crecon
  September 11, 2023

• After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
  September 8, 2023

• Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
  September 8, 2023

• Daiichi Sankyo Files XBB.1.5 COVID Jab, Eyes Japan Rollout by Year-End
  September 8, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 121
• 122
• 123
• 124
• 125
• 126
• 127
• 128
• 129
• …
• Next ›
• 最終 »